1 / 13

NMR and Mass Spectrometry approaches to metabolomics in man and mouse

NMR and Mass Spectrometry approaches to metabolomics in man and mouse. Dr. Julian Griffin jlg40@mole.bio.cam.ac.uk Dept of Biochemistry, University of Cambridge. Overview. What is metabolomics and why do we need it? Type II diabetes Man, mouse and rat CAD and cardiovascular disease

emily
Télécharger la présentation

NMR and Mass Spectrometry approaches to metabolomics in man and mouse

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NMR and Mass Spectrometry approaches to metabolomics in man and mouse Dr. Julian Griffin jlg40@mole.bio.cam.ac.uk Dept of Biochemistry, University of Cambridge

  2. Overview • What is metabolomics and why do we need it? • Type II diabetes • Man, mouse and rat • CAD and cardiovascular disease • Markers of drug efficacy • Type I diabetes • Biomarker discovery

  3. The basis of metabolomics • Metabolomics/metabonomics • the quantitative measurement of metabolic responses to pathophysiological stimuli or genetic modification • Measure small molecule concentrations through a global approach • NMR spectroscopy • Mass Spectrometry • Use pattern recognition to define metabolism in a multidimensional space • metabolic phenotype • metabotype

  4. Type II diabetes • Metabolism is very easily compared across animal models and back to humans • With Roger Cox, Michael Cheeseman and Tertius Hough looked at the effects of age and gender on the profile of diabetic urine • Ignored glucose! • Identified a number of novel perturbations • E.g. NMN and nucleotide metabolism PCA of 160 urine samples from a diabetic mouse model (dbdb mouse maintained at MRC Harwell). Class 1 – Male Wild Type/Heterozygous; Class 2 - Male Homozygous; Class 3 - Female WT/Heterozygous; Class 4 - Female Homozygous. Salek RM, Physiol Genomics 2007

  5. CAD and cardiovascular disease • Predict the occurrence and severity of coronary artery disease using blood serum. • Blood sera collected at Papworth hospital as part of trials concerning statins • Such systems may produce significant financial savings • angiography, currently the gold standard for diagnosis. Brindle JT et al., 2002. Nat Med. 8(12), 1439-45.

  6. However, on closer inspection: • ‘Biomarkers’ are rather generic • Gender and statin treatment effect the same ‘biomarkers’ of disease • Groups must be stratified • Over fitting of the pattern recognition models is a problem Kirschenlohr et al., Nature Medicine, 2006

  7. Mouse models of atherosclerosis • Mice - C57Bl/6, LDLR-/- • Diet - Control RM1 Diet (SDS), HFCC Diet (Hope Farms) • Blood plasma (and urine)

  8. Class 2, Control High fat diet Class 2, Control Normal diet (Week 0) Class 1, Control Normal diet Class 4, LDLR-/- Normal diet (Week 0) Class 3, LDLR-/- Normal diet Class 4, LDLR -/- High fat diet Cheng KK, Physiol Genomics, 2010

  9. ANOVA-PCA Source: Analytica Chimica Acta 629 (2008) 47-55

  10. Genotype effect Diet effect RM1 diet HFCC diet LDLR -/- B6 LDLR -/- HFCC diet B6 RM1 diet ANOVA-PCA Diet + error ANOVA-PCA Gen + error

  11. Discussion & Conclusion • Metabolomics can now be used as a high throughput phenotyping tool in mice • Metabolism is also very translatable across species • Reduced variability in phenotype can simplify biomarker discovery • Mass spectrometry is much more sensitive if you know what you are looking for • Database tools are also in place to conduct this across multiple sites

  12. Acknowledgements • Collaborators • Roger Cox, Michael Cheeseman & Tertius Hough, MRC Harwell • Anne Cooke & Paola Zaccone • Andy Nicholls & John Haselden, GSK • Funders: BBSRC, EU, BHF, GlaxoSmithKline, MRC, Syngenta, Unilever & Wellcome Trust. • JLG Group (present) • Zsuszi Ament • Michael Baker • Cecilia Castro • Martin Coleston • Sue Connor • Melanie Gulston • Cheng Kian Kai • Steve Murphitt • Lee Roberts • Reza Salek • Ben Tucker • Baljit Ubhi • Xinzhu Wang • James West

More Related